NGNE

Over the past six months, Neurogene reported full-year 2025 financial results in March 2026, highlighting the completion of enrollment in the Embolden trial and FDA Breakthrough Therapy designation for NGN-401. In May 2026, the company announced first-quarter 2026 financial results, stating that approximately 90% of Embolden trial participants had been dosed. Positive momentum followed a late-June 2026 Phase 1/2 data readout for NGN-401, showing progressive improvements in Rett syndrome patients. In early July 2026, Neurogene completed an oversubscribed public offering, raising approximately $144 million. The stock saw a significant increase of +13.02% on July 6, 2026, and a +4.56% increase on August 4, 2026, following inducement grants. The company reported second-quarter 2026 financial results and updates on August 11, 2026. Redmile Group and Jeremy Green disclosed a 9.9% stake on August 14, 2026. A lock-up agreement expired on August 31, 2026, leading to a 4.5% rise as the overhang was removed. Neurogene announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference on September 8, 2026. The share price was $35.48 on September 11, 2026, a significant increase from $17.45 on September 15, 2025, and closed at $32.09 on September 18, 2026, having gained 71.8% over the past 12 months.